A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma

Science Translational Medicine - United States
doi 10.1126/scitranslmed.3002004
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Association for the Advancement of Science (AAAS)

Related search

The VHL-HIF Signaling in Renal Cell Carcinoma: Promises and Pitfalls

2012English

Inactivation of the PBRM1 Tumor Suppressor Gene Amplifies the HIF-response in VHL−/−clear Cell Renal Carcinoma

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2017English

Inhibiting the Inhibitors, PTP1B as a Therapeutic Target in Myocardial Infarction

Heart Research - Open Journal
2018English

Wogonin Inhibits Multiple Myeloma-Stimulated Angiogenesis via C-Myc/VHL/HIF-1α Signaling Axis

Oncotarget
Oncology
2015English

Mp60-09 Lim1 Oncogene as a New Therapeutic Target in Advanced Human Renal Cell Carcinoma

Journal of Urology
Urology
2017English

Survivin Is a Therapeutic Target in Merkel Cell Carcinoma

Science Translational Medicine
Medicine
2012English

Insights Into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma

Cancer Discovery
Oncology
2017English

VHL Loss Predicts Response to Aurora Kinase a Inhibitor in Renal Cell Carcinoma Cells

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via SRC-Rac1 Signaling Axis

Frontiers in Oncology
Cancer ResearchOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy